Pharmaceutical Formulations (Medium Scale) Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

The regulatory architecture for pharmaceutical formulations manufacturing is governed by the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945, administered through a dual-licensing system involving State Drug Controllers and the Central Drugs Standard Control Organisation (CDSCO). The licensing framework distinguishes between domestic sale licences and export-oriented manufacturing permissions, with USFDA or EU-GMP certification enabling premium market access. Schedule M prescribes Good Manufacturing Practice requirements that must be implemented before commencing commercial production.

• CDSCO Manufacturing Licence (Form 27/28): Application to State Drug Controller for grant of licence to manufacture for sale or distribution under Rule 76 of Drugs and Cosmetics Rules, 1945. Requires site inspection for compliance with Schedule M, including clean room classification (ISO 7 for general areas, ISO 5 for aseptic zones), equipment validation documentation, and quality control laboratory setup. Timeline: 90-180 days. Fee: ₹10,000-25,000 depending on product categories.
• WHO-GMP Certification: Voluntary certification under Schedule M-III enabling export to regulated markets. Requires process validation batches (minimum 3), cleaning validation for all product contact surfaces, and media fill tests for sterile manufacturing. Certificate issued by CDSCO or empaneled agency. This certification is prerequisite for USFDA filing and EU marketing authorisation applications.
• Central Drug Licence (Form 25/26): Mandatory for manufacturers producing drugs covered under Schedules C and C1, including antibiotics, hormones, and biologics. Threshold: If annual turnover exceeds ₹50 crore or products require central-level oversight. Separate Licence for loan licence arrangement under Rule 69 if manufacturing is outsourced.
• Pollution Control Board Consent: Consent under Water (Prevention and Control of Pollution) Act, 1974 and Air (Prevention and Control of Pollution) Act, 1981 from State Pollution Control Board. Effluent treatment plant (ETP) with minimum 200 KLD capacity required for formulations facilities. Hazardous waste authorisation under Solid Waste Management Rules, 2016 for solvent recovery residues. Application through CTO-Consent to Operate route.
• Factory Licence and Building Plan Approval: Registration under Factories Act, 1948 through State Directorate of Industrial Health and Safety. Requires approved building plan from local planning authority, fire safety clearance from Fire Department, and structural stability certificate. Labour identification number from Employees' State Insurance (ESI) Corporation if workforce exceeds 20 persons.
• GST Registration and Drug Licence Number Mapping: GST registration mandatory with input tax credit utilization on capital goods. Drug Licence Number (DLN) must be updated on GST portal for invoice-level tracking of formulation sales to registered buyers under e-invoice framework.
• Energy Conservation and Environmental Compliance: EIA Notification, 2006 applicable if project triggers Category B thresholds (minimum 10,000 L/day water consumption or 5 MW thermal input). No major environmental impact anticipated for formulations manufacturing, but environmental clearance from State Environment Impact Assessment Authority (SEIAA) may be required for expansion projects.
• Pharmacovigilance and Adverse Event Reporting System: Registration with PvPI (Pharmacovigilance Programme of India) through IPC (Indian Pharmacopoeia Commission) mandatory for licensed manufacturers. Serious Adverse Event (SAE) reporting within 15 calendar days and periodic safety update reports (PSURs) every six months for products in the market.

KAMRIT Financial Services LLP provides end-to-end regulatory filing support for pharmaceutical formulations manufacturing licences, managing CDSCO applications, Schedule M compliance documentation, pollution control consents, and factory licence coordination across State Drug Controllers in Gujarat, Himachal Pradesh, Telangana, and Maharashtra. Our team coordinates with empanelled Schedule M auditors and pollution consultants to compress the approval timeline to 150-180 days, enabling faster path to commercial production.

Pharmaceutical formulations encompass finished dosage forms, tablets, capsules, liquids, ointments, and injectables, ready for end consumption, distinct from bulk drug (API) manufacturing which constitutes the upstream value chain. Within the Indian Pharmaceutical Market (IPM), formulation sales account for 73% of total revenues, with chronic therapies growing at 14.2% CAGR versus acute therapies at 9.8%. The antidiabetic segment leads growth at 16.4% annually, followed by cardiovascular at 13.8% and CNS at 12.1%, reflecting disease burden shifts.

Controlled-release and combination formulations command 22-28% EBITDA margins versus 18-22% for conventional immediate-release tablets, influencing product portfolio decisions. The export-oriented formulations segment serving USFDA and EU-GMP markets requires separate validated lines with 34% higher CapEx per unit, but achieves 40-45% gross margins versus 35-40% for domestic-focused production. The contract development and manufacturing (CDMO) sub-segment is growing at 18.3% as multinationals derisk China-dependent supply chains, creating capacity demand at established clusters including Baddi, Sikkim, and Pithampur.

Government procurement through Jan Aushadhi stores, representing 8% of domestic formulations by volume, operates on 50-55% average margins and provides stable off-take for commodity generics.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth

Pharmaceutical formulations manufacturing requires precision equipment selection calibrated to product portfolio and regulatory pathway. For a medium-scale facility with CapEx allocation of ₹9.3 crore to ₹112 crore, the technology stack differentiates significantly based on output volume and therapeutic category. A standard tablet manufacturing line comprises granulation (rapid mixer granulator at ₹18-45 lakh per unit), drying (fluidised bed dryer at ₹25-55 lakh), milling, blending, compression (rotary tablet press at ₹35-120 lakh depending on output speed: 20,000-100,000 tablets per hour), coating (automatic coating pan at ₹30-80 lakh), and blister/strip packaging (at ₹45-150 lakh per line).

For a 500 million tablets per annum facility, total equipment CapEx ranges from ₹6.5 crore to ₹14 crore depending on automation level. Indian equipment suppliers including ACG, Pharmatech, and Romack dominate the ₹2,400 crore domestic pharmaceutical machinery market, offering 30-40% cost advantage versus GEA or IMA (Italian) equipment with comparable performance. Chinese equipment from Shanghai Tianquan and Liaoning Pharma offers 50-60% lower capital cost but carries 18-24 month spare parts availability risk and compliance concerns for regulated markets.

European lines from GEA, Bosch, and IMA are preferred for USFDA-targeted production with validation documentation support. Energy consumption benchmarks: formulations plants require 800-1,200 kWh per crore tablets produced, with HVAC and air compression accounting for 45% of energy costs. Water for injection (WFI) generation through multi-effect stills adds ₹1.2-1.8 crore to CapEx for facilities handling liquid or sterile products.

Conversion cost (manufacturing cost per unit) for tablets ranges from ₹0.35-0.85 per tablet depending on labour intensity and automation, with material cost constituting 55-65% of total production cost.

For a pharmaceutical formulations (medium scale) project at ₹9.3 crore - ₹112 crore CapEx with a 3.2 - 6.0-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

For pharmaceutical formulations (medium scale) at ₹9.3 crore - ₹112 crore CapEx and 3.2 - 6.0-year payback, the three risks KAMRIT structures mitigation around are demand-side execution risk, input-cost volatility, and regulatory-delay risk. For pharma/healthcare, additional risks are regulatory inspection (CDSCO, USFDA where exported), price-control under DPCO/NLEM, and product-liability exposure (mitigated by structured product-liability cover). The Bankable DPR contains the full three-scenario sensitivity (base / bull / bear) on revenue, gross margin, and CapEx that a credit committee needs to see.